ERIS Lifesciences Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 16, 2025, 11:09 pm

Market Cap	19,108 Cr.
Current Price	1,400
High / Low	1,594/816
Stock P/E	58.0
Book Value	204
Dividend Yield	0.52 %
ROCE	11.3 %
ROE	16.3 %
Face Value	1.00
PEG Ratio	-37.53

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for ERIS Lifesciences Ltd

Competitors of ERIS Lifesciences Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	155 Cr.	110	247/84.3	22.4	36.5	0.00 %	18.0 %	15.5 %	10.0
MPS Pharmaa Ltd	5.77 Cr.	3.02	4.33/2.75		0.80	0.00 %	9.15 %	34.9 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	45.4 Cr.	61.2	94.9/44.5	15.4	11.9	0.00 %	9.72 %	3.44 %	10.0
Gujarat Inject (Kerala) Ltd	35.2 Cr.	24.0	29.0/12.3	35.9	6.64	0.00 %	2.65 %	2.08 %	10.0
Industry Average	17,552.45 Cr	1,110.30		43.07	182.59	0.34%	16.00%	16.30%	6.24

All Competitor Stocks of ERIS Lifesciences Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	332	306	399	461	423	403	467	505	486	551	720	741	727
Expenses	210	209	269	309	286	284	297	324	311	402	470	477	477
Operating Profit	122	97	129	151	137	119	170	181	176	148	250	265	250
OPM %	37%	32%	32%	33%	32%	30%	36%	36%	36%	27%	35%	36%	34%
Other Income	5	8	3	5	2	1	1	3	4	15	2	5	4
Interest	1	1	7	7	3	9	17	16	18	33	60	59	57
Depreciation	17	18	23	29	30	35	41	42	46	54	76	80	81
Profit before tax	109	85	101	121	107	76	112	126	116	77	115	129	116
Tax %	8%	6%	8%	1%	6%	19%	17%	3%	12%	-4%	22%	25%	25%
Net Profit	101	80	93	119	100	61	94	122	101	80	89	96	87
EPS in Rs	7.41	5.91	6.96	8.85	7.49	4.81	6.98	9.07	7.55	5.22	6.11	6.73	6.14

Last Updated: March 3, 2025, 4:35 pm

Below is a detailed analysis of the quarterly data for ERIS Lifesciences Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is 727.00 Cr.. The value appears to be declining and may need further review. It has decreased from 741.00 Cr. (Sep 2024) to 727.00 Cr., marking a decrease of 14.00 Cr..
For Expenses, as of Dec 2024, the value is 477.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 477.00 Cr..
For Operating Profit, as of Dec 2024, the value is 250.00 Cr.. The value appears to be declining and may need further review. It has decreased from 265.00 Cr. (Sep 2024) to 250.00 Cr., marking a decrease of 15.00 Cr..
For OPM %, as of Dec 2024, the value is 34.00%. The value appears to be declining and may need further review. It has decreased from 36.00% (Sep 2024) to 34.00%, marking a decrease of 2.00%.
For Other Income, as of Dec 2024, the value is 4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Sep 2024) to 4.00 Cr., marking a decrease of 1.00 Cr..
For Interest, as of Dec 2024, the value is 57.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 59.00 Cr. (Sep 2024) to 57.00 Cr., marking a decrease of 2.00 Cr..
For Depreciation, as of Dec 2024, the value is 81.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 80.00 Cr. (Sep 2024) to 81.00 Cr., marking an increase of 1.00 Cr..
For Profit before tax, as of Dec 2024, the value is 116.00 Cr.. The value appears to be declining and may need further review. It has decreased from 129.00 Cr. (Sep 2024) to 116.00 Cr., marking a decrease of 13.00 Cr..
For Tax %, as of Dec 2024, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 25.00%.
For Net Profit, as of Dec 2024, the value is 87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 96.00 Cr. (Sep 2024) to 87.00 Cr., marking a decrease of 9.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 6.14. The value appears to be declining and may need further review. It has decreased from 6.73 (Sep 2024) to 6.14, marking a decrease of 0.59.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:22 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	393	509	546	597	750	856	982	1,074	1,212	1,347	1,685	2,009	2,739
Expenses	307	414	427	425	480	533	637	702	781	858	1,146	1,332	1,826
Operating Profit	86	95	118	172	269	322	345	372	431	489	539	677	913
OPM %	22%	19%	22%	29%	36%	38%	35%	35%	36%	36%	32%	34%	33%
Other Income	1	9	7	3	25	26	31	12	9	22	9	22	26
Interest	1	0	0	0	1	11	23	2	2	4	26	85	210
Depreciation	3	5	16	20	23	26	36	50	43	65	117	183	292
Profit before tax	83	98	109	154	270	312	317	331	394	442	405	431	437
Tax %	30%	28%	18%	13%	9%	6%	8%	11%	10%	8%	8%	8%
Net Profit	58	71	89	135	247	295	291	297	355	406	374	397	352
EPS in Rs	4,232.73	5,121.45	6,489.45	9,714.18	17.95	21.39	21.15	21.84	26.16	29.88	28.10	28.82	24.20
Dividend Payout %	0%	0%	0%	63%	0%	0%	0%	13%	21%	20%	26%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	22.41%	25.35%	51.69%	82.96%	19.43%	-1.36%	2.06%	19.53%	14.37%	-7.88%	6.15%
Change in YoY Net Profit Growth (%)	0.00%	2.94%	26.33%	31.28%	-63.53%	-20.79%	3.42%	17.47%	-5.16%	-22.25%	14.03%

ERIS Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	15%
5 Years:	15%
3 Years:	18%
TTM:	47%

Compounded Profit Growth
10 Years:	19%
5 Years:	6%
3 Years:	3%
TTM:	-13%

Stock Price CAGR
10 Years:	%
5 Years:	23%
3 Years:	26%
1 Year:	59%

Return on Equity
10 Years:	25%
5 Years:	20%
3 Years:	19%
Last Year:	16%

Last Updated: Unknown

Balance Sheet

Last Updated: January 13, 2025, 3:47 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	0.14	0.14	0.14	0.14	14	14	14	14	14	14	14	14	14
Reserves	106	176	266	299	553	848	1,137	1,283	1,563	1,895	2,182	2,573	2,758
Borrowings	3	1	1	0	1	377	176	0	7	84	877	2,781	2,735
Other Liabilities	63	94	91	98	124	170	175	205	202	233	337	1,375	1,516
Total Liabilities	172	271	357	397	692	1,408	1,502	1,502	1,785	2,226	3,410	6,742	7,022
Fixed Assets	27	75	72	71	232	771	761	875	854	918	2,568	4,328	5,295
CWIP	0	0	0	0	0	0	3	4	2	27	22	20	7
Investments	47	84	167	190	303	365	356	78	294	520	37	16	79
Other Assets	98	112	119	136	157	271	383	544	636	761	783	2,379	1,641
Total Assets	172	271	357	397	692	1,408	1,502	1,502	1,785	2,226	3,410	6,742	7,022

Below is a detailed analysis of the balance sheet data for ERIS Lifesciences Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
For Reserves, as of Sep 2024, the value is ₹2,758.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,573.00 Cr. (Mar 2024) to ₹2,758.00 Cr., marking an increase of 185.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹2,735.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,781.00 Cr. (Mar 2024) to ₹2,735.00 Cr., marking a decrease of 46.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹1,516.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,375.00 Cr. (Mar 2024) to ₹1,516.00 Cr., marking an increase of 141.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹7,022.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,742.00 Cr. (Mar 2024) to ₹7,022.00 Cr., marking an increase of 280.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹5,295.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,328.00 Cr. (Mar 2024) to ₹5,295.00 Cr., marking an increase of 967.00 Cr..
For CWIP, as of Sep 2024, the value is ₹7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Mar 2024) to ₹7.00 Cr., marking a decrease of 13.00 Cr..
For Investments, as of Sep 2024, the value is ₹79.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2024) to ₹79.00 Cr., marking an increase of 63.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹1,641.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,379.00 Cr. (Mar 2024) to ₹1,641.00 Cr., marking a decrease of 738.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹7,022.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,742.00 Cr. (Mar 2024) to ₹7,022.00 Cr., marking an increase of 280.00 Cr..

Notably, the Reserves (2,758.00 Cr.) exceed the Borrowings (2,735.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	38	90	90	131	200	235	223	271	375	378	292	486
Cash from Investing Activity +	-36	-83	-92	-44	-184	-590	-5	123	-323	-320	-975	-1,828
Cash from Financing Activity +	-3	-2	0	-84	-24	363	-221	-335	-82	-45	688	1,380
Net Cash Flow	-1	5	-2	4	-8	8	-3	60	-30	14	5	38

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	83.00	94.00	117.00	172.00	268.00	-55.00	169.00	372.00	424.00	405.00	-338.00	675.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	15	16	16	16	24	28	31	53	42	44	63	77
Inventory Days	214	166	223	178	195	178	196	148	145	166	136	182
Days Payable	109	138	142	92	134	247	200	213	157	166	129	258
Cash Conversion Cycle	120	43	97	102	84	-40	28	-12	30	44	70	0
Working Capital Days	31	7	15	9	23	-13	-17	59	64	76	92	83
ROCE %	98%	64%	47%	53%	60%	34%	26%	25%	27%	25%	17%	11%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
Promoters	52.68%	52.66%	52.66%	52.30%	52.29%	52.70%	52.86%	52.86%	54.91%	54.90%	54.90%	54.88%
FIIs	13.60%	13.34%	13.31%	15.35%	15.39%	15.50%	14.86%	13.78%	13.20%	13.13%	14.27%	14.59%
DIIs	9.94%	10.37%	10.50%	10.66%	10.69%	9.95%	10.02%	10.73%	14.52%	14.55%	15.63%	16.23%
Public	23.78%	23.62%	23.52%	21.69%	21.63%	21.85%	22.27%	22.63%	17.37%	17.41%	15.20%	14.30%
No. of Shareholders	49,833	54,223	57,061	51,639	48,055	46,746	45,931	44,169	42,245	46,496	51,753	44,176

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
HDFC Small Cap Fund - Regular Plan	5,098,713	1.89	438.23	5,098,713	2025-04-14	0%
UTI Flexi Cap Fund	2,573,067	0.91	221.16	2,573,067	2025-04-12	0%
Franklin India Smaller Companies Fund	1,710,900	1.52	147.05	1,710,900	2025-04-14	0%
Aditya Birla Sun Life Equity Hybrid 95 Fund	1,368,030	1.7	117.58	1,368,030	2025-04-15	0%
UTI Value Fund	1,029,126	1.19	88.45	1,029,126	2025-04-11	0%
HSBC Midcap Fund	962,580	1.03	82.73	962,580	2025-04-12	0%
HDFC Large and Mid Cap Fund - Regular Plan	675,000	0.49	58.02	675,000	2025-04-12	0%
UTI Mid Cap Fund	591,612	0.58	50.85	591,612	2025-04-13	0%
Tata ELSS Tax Saver Fund	512,000	1.27	44.01	512,000	2025-04-12	0%
UTI Dividend Yield Fund	450,000	1.26	38.68	450,000	2025-04-14	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	28.82	28.10	29.89	26.16	21.61
Diluted EPS (Rs.)	28.79	28.07	29.88	26.14	21.59
Cash EPS (Rs.)	42.61	36.12	34.61	29.32	25.54
Book Value[Excl.RevalReserv]/Share (Rs.)	190.11	163.30	140.35	116.10	95.47
Book Value[Incl.RevalReserv]/Share (Rs.)	190.11	163.30	140.35	116.10	95.47
Revenue From Operations / Share (Rs.)	147.70	123.92	99.10	89.25	79.10
PBDIT / Share (Rs.)	51.36	40.29	37.60	32.35	28.26
PBIT / Share (Rs.)	37.94	31.68	32.84	29.19	24.56
PBT / Share (Rs.)	31.70	29.76	32.53	29.05	24.40
Net Profit / Share (Rs.)	29.19	27.51	29.85	26.16	21.84
NP After MI And SOA / Share (Rs.)	28.82	28.10	29.88	26.16	21.84
PBDIT Margin (%)	34.77	32.51	37.93	36.24	35.73
PBIT Margin (%)	25.68	25.56	33.13	32.70	31.05
PBT Margin (%)	21.46	24.01	32.82	32.55	30.85
Net Profit Margin (%)	19.76	22.20	30.12	29.30	27.60
NP After MI And SOA Margin (%)	19.50	22.67	30.14	29.30	27.60
Return on Networth / Equity (%)	15.15	17.40	21.28	22.52	22.87
Return on Capital Employeed (%)	11.42	13.36	21.53	23.76	24.03
Return On Assets (%)	5.56	10.42	17.87	19.35	19.10
Long Term Debt / Equity (X)	0.25	0.29	0.02	0.00	0.00
Total Debt / Equity (X)	1.06	0.37	0.02	0.00	0.00
Asset Turnover Ratio (%)	0.37	0.52	0.61	0.67	0.67
Current Ratio (X)	0.90	1.73	3.14	2.80	2.91
Quick Ratio (X)	0.83	1.43	2.55	2.23	2.49
Inventory Turnover Ratio (X)	1.11	1.26	1.31	1.48	1.04
Dividend Payout Ratio (NP) (%)	0.00	26.15	20.10	21.02	13.14
Dividend Payout Ratio (CP) (%)	0.00	20.01	17.34	18.75	11.23
Earning Retention Ratio (%)	0.00	73.85	79.90	78.98	86.86
Cash Earning Retention Ratio (%)	0.00	79.99	82.66	81.25	88.77
Interest Coverage Ratio (X)	8.24	20.94	123.26	243.78	177.51
Interest Coverage Ratio (Post Tax) (X)	5.68	15.30	98.87	198.08	138.14
Enterprise Value (Cr.)	13413.39	8575.56	9359.51	8168.96	4936.17
EV / Net Operating Revenue (X)	6.68	5.09	6.95	6.74	4.60
EV / EBITDA (X)	19.20	15.65	18.31	18.60	12.86
MarketCap / Net Operating Revenue (X)	5.70	4.62	6.95	6.77	4.66
Retention Ratios (%)	0.00	73.84	79.89	78.97	86.85
Price / BV (X)	4.42	3.54	4.91	5.21	3.86
Price / Net Operating Revenue (X)	5.70	4.62	6.95	6.77	4.66
EarningsYield	0.03	0.04	0.04	0.04	0.05

After reviewing the key financial ratios for ERIS Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 24, the value is 28.82. This value is within the healthy range. It has increased from 28.10 (Mar 23) to 28.82, marking an increase of 0.72.
For Diluted EPS (Rs.), as of Mar 24, the value is 28.79. This value is within the healthy range. It has increased from 28.07 (Mar 23) to 28.79, marking an increase of 0.72.
For Cash EPS (Rs.), as of Mar 24, the value is 42.61. This value is within the healthy range. It has increased from 36.12 (Mar 23) to 42.61, marking an increase of 6.49.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 190.11. It has increased from 163.30 (Mar 23) to 190.11, marking an increase of 26.81.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 190.11. It has increased from 163.30 (Mar 23) to 190.11, marking an increase of 26.81.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 147.70. It has increased from 123.92 (Mar 23) to 147.70, marking an increase of 23.78.
For PBDIT / Share (Rs.), as of Mar 24, the value is 51.36. This value is within the healthy range. It has increased from 40.29 (Mar 23) to 51.36, marking an increase of 11.07.
For PBIT / Share (Rs.), as of Mar 24, the value is 37.94. This value is within the healthy range. It has increased from 31.68 (Mar 23) to 37.94, marking an increase of 6.26.
For PBT / Share (Rs.), as of Mar 24, the value is 31.70. This value is within the healthy range. It has increased from 29.76 (Mar 23) to 31.70, marking an increase of 1.94.
For Net Profit / Share (Rs.), as of Mar 24, the value is 29.19. This value is within the healthy range. It has increased from 27.51 (Mar 23) to 29.19, marking an increase of 1.68.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 28.82. This value is within the healthy range. It has increased from 28.10 (Mar 23) to 28.82, marking an increase of 0.72.
For PBDIT Margin (%), as of Mar 24, the value is 34.77. This value is within the healthy range. It has increased from 32.51 (Mar 23) to 34.77, marking an increase of 2.26.
For PBIT Margin (%), as of Mar 24, the value is 25.68. This value exceeds the healthy maximum of 20. It has increased from 25.56 (Mar 23) to 25.68, marking an increase of 0.12.
For PBT Margin (%), as of Mar 24, the value is 21.46. This value is within the healthy range. It has decreased from 24.01 (Mar 23) to 21.46, marking a decrease of 2.55.
For Net Profit Margin (%), as of Mar 24, the value is 19.76. This value exceeds the healthy maximum of 10. It has decreased from 22.20 (Mar 23) to 19.76, marking a decrease of 2.44.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 19.50. This value is within the healthy range. It has decreased from 22.67 (Mar 23) to 19.50, marking a decrease of 3.17.
For Return on Networth / Equity (%), as of Mar 24, the value is 15.15. This value is within the healthy range. It has decreased from 17.40 (Mar 23) to 15.15, marking a decrease of 2.25.
For Return on Capital Employeed (%), as of Mar 24, the value is 11.42. This value is within the healthy range. It has decreased from 13.36 (Mar 23) to 11.42, marking a decrease of 1.94.
For Return On Assets (%), as of Mar 24, the value is 5.56. This value is within the healthy range. It has decreased from 10.42 (Mar 23) to 5.56, marking a decrease of 4.86.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.25. This value is within the healthy range. It has decreased from 0.29 (Mar 23) to 0.25, marking a decrease of 0.04.
For Total Debt / Equity (X), as of Mar 24, the value is 1.06. This value exceeds the healthy maximum of 1. It has increased from 0.37 (Mar 23) to 1.06, marking an increase of 0.69.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.37. It has decreased from 0.52 (Mar 23) to 0.37, marking a decrease of 0.15.
For Current Ratio (X), as of Mar 24, the value is 0.90. This value is below the healthy minimum of 1.5. It has decreased from 1.73 (Mar 23) to 0.90, marking a decrease of 0.83.
For Quick Ratio (X), as of Mar 24, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.43 (Mar 23) to 0.83, marking a decrease of 0.60.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.11. This value is below the healthy minimum of 4. It has decreased from 1.26 (Mar 23) to 1.11, marking a decrease of 0.15.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 26.15 (Mar 23) to 0.00, marking a decrease of 26.15.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 20.01 (Mar 23) to 0.00, marking a decrease of 20.01.
For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 73.85 (Mar 23) to 0.00, marking a decrease of 73.85.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 79.99 (Mar 23) to 0.00, marking a decrease of 79.99.
For Interest Coverage Ratio (X), as of Mar 24, the value is 8.24. This value is within the healthy range. It has decreased from 20.94 (Mar 23) to 8.24, marking a decrease of 12.70.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 5.68. This value is within the healthy range. It has decreased from 15.30 (Mar 23) to 5.68, marking a decrease of 9.62.
For Enterprise Value (Cr.), as of Mar 24, the value is 13,413.39. It has increased from 8,575.56 (Mar 23) to 13,413.39, marking an increase of 4,837.83.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 6.68. This value exceeds the healthy maximum of 3. It has increased from 5.09 (Mar 23) to 6.68, marking an increase of 1.59.
For EV / EBITDA (X), as of Mar 24, the value is 19.20. This value exceeds the healthy maximum of 15. It has increased from 15.65 (Mar 23) to 19.20, marking an increase of 3.55.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.70. This value exceeds the healthy maximum of 3. It has increased from 4.62 (Mar 23) to 5.70, marking an increase of 1.08.
For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 73.84 (Mar 23) to 0.00, marking a decrease of 73.84.
For Price / BV (X), as of Mar 24, the value is 4.42. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 23) to 4.42, marking an increase of 0.88.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.70. This value exceeds the healthy maximum of 3. It has increased from 4.62 (Mar 23) to 5.70, marking an increase of 1.08.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 23) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of ERIS Lifesciences Ltd as of April 17, 2025 is: 1,550.92

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 17, 2025, ERIS Lifesciences Ltd is Undervalued by 10.78% compared to the current share price 1,400.00

Intrinsic Value of ERIS Lifesciences Ltd as of April 17, 2025 is: 1,526.95

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 17, 2025, ERIS Lifesciences Ltd is Undervalued by 9.07% compared to the current share price 1,400.00

Last 5 Year EPS CAGR: -1.55%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 40.58%, which is a positive sign. The company has higher reserves (1,203.00 cr) compared to borrowings (541.77 cr), indicating strong financial stability. The company has shown consistent growth in sales (357.00 cr) and profit (291.00 cr) over the years.	The stock has a high average Working Capital Days of 35.75, which may not be favorable. The stock has a high average Cash Conversion Cycle of 47.17, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ERIS Lifesciences Ltd:
1. Net Profit Margin: 19.76%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 11.42% (Industry Average ROCE: 16%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 15.15% (Industry Average ROE: 16.3%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 5.68
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 0.83
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 58 (Industry average Stock P/E: 43.07)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 1.06
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1486.71 Cr. and Equity Capital is Rs. 13.60 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Ahmedabad Gujarat 380054	complianceofficer@erislifesciences.com http://www.eris.co.in

Management
Name	Position Held
Mr. Amit Bakshi	Chairperson & Managing Director
Mr. Krishnakumar Vaidyanathan	COO & Executive Director
Mr. Inderjeet Singh Negi	Executive Director
Mr. Kaushal Shah	Executive Director
Mr. Rajeev Dalal	Independent Director
Mr. Sujesh Vasudevan	Independent Director
Ms. Kalpana Unadkat	Independent Director
Mr. Prashant Gupta	Independent Director

FAQ

What is the intrinsic value of ERIS Lifesciences Ltd?

ERIS Lifesciences Ltd's intrinsic value (as of 17 April 2025) is ₹1550.92 — 10.78% higher the current market price of 1,400.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 19,108 Cr. market cap, FY2025-2026 high/low of ₹1,594/816, reserves of 2,758 Cr, and liabilities of 7,022 Cr.

What is the Market Cap of ERIS Lifesciences Ltd?

The Market Cap of ERIS Lifesciences Ltd is 19,108 Cr..

What is the current Stock Price of ERIS Lifesciences Ltd as on 17 April 2025?

The current stock price of ERIS Lifesciences Ltd as on 17 April 2025 is 1,400.

What is the High / Low of ERIS Lifesciences Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of ERIS Lifesciences Ltd stocks is ₹1,594/816.

What is the Stock P/E of ERIS Lifesciences Ltd?

The Stock P/E of ERIS Lifesciences Ltd is 58.0.

What is the Book Value of ERIS Lifesciences Ltd?

The Book Value of ERIS Lifesciences Ltd is 204.

What is the Dividend Yield of ERIS Lifesciences Ltd?

The Dividend Yield of ERIS Lifesciences Ltd is 0.52 %.

What is the ROCE of ERIS Lifesciences Ltd?

The ROCE of ERIS Lifesciences Ltd is 11.3 %.

What is the ROE of ERIS Lifesciences Ltd?

The ROE of ERIS Lifesciences Ltd is 16.3 %.

What is the Face Value of ERIS Lifesciences Ltd?

The Face Value of ERIS Lifesciences Ltd is 1.00.